• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-07-03

  0.4% Trypan Blue Solution provides a standardized, exclusion-based method for distinguishing live and dead cells, supporting accurate cell viability measurement in cell culture and cytotoxicity assays. This formulation is not suitable for diagnostic or clinical use, but is essential for research workflows requiring reliable live/dead cell discrimination.

• DiscoveryProbe™ L1023: Uncovering Apoptosis Pathways in Canc

  2026-07-02

  Explore how the L1023 Anti-Cancer Compound Library empowers targeted exploration of apoptosis and resistance mechanisms in cancer research. This article reveals advanced assay strategies and the practical impact of recent MCL1 inhibitor discoveries.

• HSP90 Modulates RNA Foci in Myotonic Dystrophy Type 1 Myobla

  2026-07-02

  This study used an unbiased small molecule screen to uncover HSP90 as a novel regulator of DMPK mRNA expression and RNA foci formation in Myotonic Dystrophy type 1 (DM1) cells. These findings clarify the molecular mechanisms of DM1 pathogenesis and highlight new directions for therapeutic intervention.

• GTP Solution (100 mM): Foundation for mRNA Synthesis & Signa

  2026-07-01

  GTP Solution (100 mM) enables high-fidelity in vitro transcription and is essential for synthesizing functional mRNA, as demonstrated in recent bladder cancer research. Its ≥99% purity and stringent contaminant control make it optimal for sensitive applications. This article reviews its mechanistic role, application benchmarks, and integration into advanced molecular workflows.

• Arrb2-Mediated M2 Macrophage Polarization Reduces Liver IRI

  2026-07-01

  This study elucidates a novel hepatocyte-intrinsic mechanism where Arrb2 upregulates 6-ketoLCA, promoting M2 macrophage polarization and thereby mitigating hepatic ischemia–reperfusion injury (IRI). These findings offer new insight into immunomodulatory pathways that could improve liver transplantation outcomes.

• Ruxolitinib (INCB018424): Protocols and Innovations in JAK-S

  2026-06-30

  Ruxolitinib (INCB018424) is redefining myeloproliferative disorder research through high-dimensional immune profiling and combinatorial immunomodulation. This article synthesizes advanced protocol guidance, key troubleshooting insights, and the latest innovations in spectral cytometry—empowering researchers to unlock new frontiers in JAK-STAT pathway inhibition.

• Triacetin in Biochemical Research: Workflows, Use-Cases & Op

  2026-06-30

  Triacetin (glyceryl triacetate) stands out as a versatile lipid-related biochemical reagent, enabling advanced metabolic and antitumor assays with precise dosing and robust safety margins. This guide delivers protocol-ready workflows, troubleshooting strategies, and a translation of the latest mechanistic insights to maximize reproducibility and impact in life science research.

• CX-5461: Mechanistic Insights and Strategic Assay Design in

  2026-06-29

  Explore the multifaceted role of CX-5461 as a potent RNA polymerase I inhibitor in cancer research. This article reveals unique mechanistic insights, advanced protocol guidance, and practical applications, offering a deeper perspective for designing high-impact studies.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Innova

  2026-06-29

  This study establishes intravesical delivery of p21 mRNA-loaded lipid nanoparticles as a potent tumor suppressor replacement strategy for non-muscle-invasive bladder cancer. The findings demonstrate robust restoration of p21 expression, suppression of tumor growth, and minimal systemic toxicity, highlighting a clinically relevant approach for localized mRNA-based cancer therapy.

• Tranexamic Acid as an Antifibrinolytic Agent: Workflows & In

  2026-06-28

  Tranexamic Acid is redefining antifibrinolytic research with robust clot-stabilization and infection-control capabilities, as demonstrated in advanced bi-layer wound dressings. Leveraging high-purity APExBIO Tranexamic Acid enables reproducible protocols and translational insights for trauma and wound care models.

• LY2603618: Precision Chk1 Inhibition for Biomarker-Guided Ca

  2026-06-27

  Explore the advanced application of LY2603618, a selective Chk1 inhibitor, as a DNA damage response tool in biomarker-guided cancer research. This article uniquely examines PPP2R2A as a predictive marker, offering fresh, actionable insights beyond standard protocols.

• Cy5.5 NHS Ester: Advanced Near-Infrared Dye for In Vivo Imag

  2026-06-26

  Cy5.5 NHS ester (non-sulfonated) empowers precise protein and nanoparticle labeling, enabling high-sensitivity near-infrared fluorescence imaging for in vivo applications. This article details protocol enhancements, troubleshooting, and translational applications—such as blood-brain barrier-crossing nanoparticles—anchored in the latest research.

• High-Throughput In Vitro BBB Permeability Prediction Model

  2026-06-26

  This study introduces a robust high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells in a Transwell system, with integrated correction for lysosomal trapping. The model demonstrates reliable prediction of CNS drug permeability, streamlining early-stage screening and de-risking central nervous system (CNS) drug development.

• GTP Solution (100 mM): Enabling Precision mRNA Synthesis & T

  2026-06-25

  Explore how GTP Solution (100 mM) empowers high-fidelity mRNA synthesis and advances tumor suppressor research in bladder cancer. This cornerstone article reveals mechanisms, protocol parameters, and unique insights not covered elsewhere.

• Indole-3-pyruvic Acid Feedback Regulates Auxin Biosynthesis

  2026-06-25

  This study reveals that indole-3-pyruvic acid (IPA) acts as a negative feedback inhibitor of TAA1, coordinating the two-step auxin biosynthesis pathway in plants. These findings clarify a central regulatory mechanism for indole-3-acetic acid (IAA) homeostasis, with implications for plant hormone research and metabolic engineering.

14749 records 1/984 page Next 12345 下5页 Last page